Immunocore to Present Brenetafusp Phase 1 Data at SITC 2026
Oxfordshire, England; Radnor, Pennsylvania; and Gaithersburg, Maryland, US — October 29, 2026 Immunocore Holdings plc announced that it will...
Immuno-Oncology
Advertisement
OSE Immunotherapeutics Reports Positive Tedopi Phase 2 Results
Nantes, France — October 29, 2026 OSE Immunotherapeutics SA reported final positive results from its Combi-TED Phase 2 randomized...
Astellas and Audax Sign $1.34B DAX-044 Cancer Drug Deal
Tokyo, Japan, and Melbourne, Australia, October 28, 2026 Astellas Pharma Inc. and Audax Biosciences Pty Ltd have entered into...
Henlius Partners With Amberstone on Next-Gen TCEs
Shanghai, China, September 24, 2026 Henlius has announced a strategic partnership with Amberstone Biosciences to discover and develop next-generation...
Leads Biolabs Gains Japan Orphan Drug Designation for Opamtistomig
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
Advertisements
Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
C4 Therapeutics Presents Cemsidomide Biomarker Data in Multiple Myeloma
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
AstraZeneca Gains US Priority Review for IMFINZI in MIBC
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
AIM Highlights Ampligen Potential in Pancreatic Cancer
OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...
MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC
CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...
Advertisement
